Why Are There So Few FDA-Approved Therapeutics for Wound Healing?
Since the only and the milestone FDA approval of becaplermin gel (Regranex<sup>TM</sup>, 0.01% human recombinant PDGF-BB) as a (diabetic) wound healing therapeutic more than 25 years ago, no new therapeutic (excluding physical therapies, devices, dressings, anti-microbial agents, or othe...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/20/15109 |
| _version_ | 1797573716620607488 |
|---|---|
| author | Mei Chen Cheng Chang Brandon Levian David T. Woodley Wei Li |
| author_facet | Mei Chen Cheng Chang Brandon Levian David T. Woodley Wei Li |
| author_sort | Mei Chen |
| collection | DOAJ |
| description | Since the only and the milestone FDA approval of becaplermin gel (Regranex<sup>TM</sup>, 0.01% human recombinant PDGF-BB) as a (diabetic) wound healing therapeutic more than 25 years ago, no new therapeutic (excluding physical therapies, devices, dressings, anti-microbial agents, or other preventive treatments) for any type of wound healing has advanced to clinical applications. During the same period of time, the FDA has approved additional 250 new drugs for various human tumors, which were famously described as “wounds that do not heal”. Two similar pathological conditions have experienced such a dramatic difference in therapeutics. More surprisingly, few in the wound healing community seem to be alarmed by this mysterious deficit. As it is often said, “damaging is far easier than re-building”. In contrast to the primary duty of a cancer drug to damage a single molecule of the signaling network, a wound healing drug must be able to re-build the multi-level damages in the wound. No known single molecule alone is capable of repairing multi-cell-type and multi-pathway damages all at once. We argue that the previous single molecule-based strategy for developing wound healing therapeutics is profoundly flawed in theory. The future success of effective wound healing therapeutics requires a fundamental change in the paradigm. |
| first_indexed | 2024-03-10T21:12:59Z |
| format | Article |
| id | doaj.art-a46489b49ade46c2a1cf2fe18dcef915 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T21:12:59Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a46489b49ade46c2a1cf2fe18dcef9152023-11-19T16:41:45ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-10-0124201510910.3390/ijms242015109Why Are There So Few FDA-Approved Therapeutics for Wound Healing?Mei Chen0Cheng Chang1Brandon Levian2David T. Woodley3Wei Li4Department of Dermatology, USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Center, Los Angeles, CA 90033, USADepartment of Dermatology, USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Center, Los Angeles, CA 90033, USADepartment of Dermatology, USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Center, Los Angeles, CA 90033, USADepartment of Dermatology, USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Center, Los Angeles, CA 90033, USADepartment of Dermatology, USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Center, Los Angeles, CA 90033, USASince the only and the milestone FDA approval of becaplermin gel (Regranex<sup>TM</sup>, 0.01% human recombinant PDGF-BB) as a (diabetic) wound healing therapeutic more than 25 years ago, no new therapeutic (excluding physical therapies, devices, dressings, anti-microbial agents, or other preventive treatments) for any type of wound healing has advanced to clinical applications. During the same period of time, the FDA has approved additional 250 new drugs for various human tumors, which were famously described as “wounds that do not heal”. Two similar pathological conditions have experienced such a dramatic difference in therapeutics. More surprisingly, few in the wound healing community seem to be alarmed by this mysterious deficit. As it is often said, “damaging is far easier than re-building”. In contrast to the primary duty of a cancer drug to damage a single molecule of the signaling network, a wound healing drug must be able to re-build the multi-level damages in the wound. No known single molecule alone is capable of repairing multi-cell-type and multi-pathway damages all at once. We argue that the previous single molecule-based strategy for developing wound healing therapeutics is profoundly flawed in theory. The future success of effective wound healing therapeutics requires a fundamental change in the paradigm.https://www.mdpi.com/1422-0067/24/20/15109wound healingtherapeuticsbuilder vs damager |
| spellingShingle | Mei Chen Cheng Chang Brandon Levian David T. Woodley Wei Li Why Are There So Few FDA-Approved Therapeutics for Wound Healing? International Journal of Molecular Sciences wound healing therapeutics builder vs damager |
| title | Why Are There So Few FDA-Approved Therapeutics for Wound Healing? |
| title_full | Why Are There So Few FDA-Approved Therapeutics for Wound Healing? |
| title_fullStr | Why Are There So Few FDA-Approved Therapeutics for Wound Healing? |
| title_full_unstemmed | Why Are There So Few FDA-Approved Therapeutics for Wound Healing? |
| title_short | Why Are There So Few FDA-Approved Therapeutics for Wound Healing? |
| title_sort | why are there so few fda approved therapeutics for wound healing |
| topic | wound healing therapeutics builder vs damager |
| url | https://www.mdpi.com/1422-0067/24/20/15109 |
| work_keys_str_mv | AT meichen whyaretheresofewfdaapprovedtherapeuticsforwoundhealing AT chengchang whyaretheresofewfdaapprovedtherapeuticsforwoundhealing AT brandonlevian whyaretheresofewfdaapprovedtherapeuticsforwoundhealing AT davidtwoodley whyaretheresofewfdaapprovedtherapeuticsforwoundhealing AT weili whyaretheresofewfdaapprovedtherapeuticsforwoundhealing |